Literature DB >> 11978506

Can PK/PD be used in everyday clinical practice.

Francesco Scaglione1.   

Abstract

Over the last decade much insight has been gained in the relationships between dosing regimens of antimicrobials and bacterial eradication and clinical efficacy. These pharmacokinetic-pharmacodynamic (PK/PD) relationships have become available as tools in individualising antimicrobial therapy. To be able to do this, the PK parameters of the antimicrobial in the individual patient have to be known or estimated, and the MIC of the micro-organism causing the infection, known. In our hospital, we have started a programme using this approach. Preliminary results suggest that dose optimisation leads to increased efficacy and lower costs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978506     DOI: 10.1016/s0924-8579(02)00020-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

5.  Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.

Authors:  A M Haritova; N V Rusenova; P R Parvanov; L D Lashev; J Fink-Gremmels
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

6.  Outcome evaluation of an intervention to improve the effective and safe use of meropenem.

Authors:  Yusuke Yagi; Masafumi Okazaki; Hiromi Higaki; Megumi Nakai; Ayumu Hirata; Mitsuhiko Miyamura
Journal:  Int J Clin Pharm       Date:  2014-04-20

7.  Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.

Authors:  Jan J De Waele; J Lipman; M Akova; M Bassetti; G Dimopoulos; M Kaukonen; D Koulenti; C Martin; P Montravers; J Rello; A Rhodes; A A Udy; T Starr; S C Wallis; J A Roberts
Journal:  Intensive Care Med       Date:  2014-07-23       Impact factor: 17.440

8.  The case for precision dosing: medical conservatism does not justify inaction.

Authors:  Marc H Scheetz; Thomas P Lodise; Kevin J Downes; George Drusano; Michael Neely
Journal:  J Antimicrob Chemother       Date:  2021-06-18       Impact factor: 5.790

9.  An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.

Authors:  Almath M Spooner; Catherine Deegan; Deirdre M D'Arcy; Caitriona M Gowing; Maria B Donnelly; Owen I Corrigan
Journal:  BMC Clin Pharmacol       Date:  2011-08-04

10.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.